Rush University Medical Center Infectious Disease

Topics

• Antimicrobial Resistance in Staphylococcus 133
• Antibiotic Resistance in Bacteria 131
• HIV/AIDS Research and Interventions 96
• HIV Research and Treatment 91
• Hepatitis C virus research 73
• Antibiotic Use and Resistance 65
• HIV/AIDS drug development and treatment 63
• HIV-related health complications and treatments 63
• Antifungal resistance and susceptibility 60
• Infection Control in Healthcare 58
• Fungal Infections and Studies 51
• Reproductive tract infections research 49

Most cited

1. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19.

   The New England journal of medicine · 2021 · 1,044 citations · Gregory Huhn

2. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia.

   The New England journal of medicine · 2021 · 798 citations · Mariam Aziz

3. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.

   JAMA · 2021 · 739 citations · Gregory Huhn

4. Epidemiologic and Clinical Characteristics of Monkeypox Cases - United States, May 17-July 22, 2022.

   MMWR. Morbidity and mortality weekly report · 2022 · 322 citations · Stephanie Black

5. Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19.

   The New England journal of medicine · 2021 · 533 citations · Gregory Huhn

6. Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study.

   The Lancet. Infectious diseases · 2025 · 69 citations · Monica Sikka